Analysis of different dosages of methylene blue in cultivated keratinocytes from burned patients

• Grant number: 16/20374-0
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: September 01, 2017
• End date: August 31, 2018
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Alfredo Gragnani Filho
• Grantee: Eduarda Carneiro de Carvalho Junqueira
• Host Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

Burn is a major challenge to public health and many victims are affected by this trauma. In 2004, there were over 11 million burned, reaching estimated 300,000 deaths per year related to burning by fire. The burned patient treatment becomes a challenge because of its high cost, including inpatient long-term, multiple surgical procedures and intensive use of equipment, drugs and expensive consumables. Methylene blue (MB) is a heterocyclic aromatic compound, dark green solid, water soluble, produces blue solution, odorless, with molecular formula, C16H18CIN3S, and has been used for more than a century for a variety of purposes, including antimalarial treatment during World War II and treatment for cyanide poisoning. It continues to be an effective treatment for methemoglobinemia is used for lymphatic mapping, and serves as a marker for urine leakage during surgery. In addition, methylene blue have been studied and used as adjuvant therapy for several vasoplegia resulting shock states. Septic shock is a major cause of morbidity and mortality in the intensive care unit, and effective therapies are limited. Methylene blue is a selective inhibitor of guanylate cyclase, a second messenger involved in vasodilation mediated by nitric oxide. Observational studies with methylene blue have shown beneficial effects on hemodynamics and oxygen supply. Its dosage should be screened in order to avoid possible adverse effects. Objective: To evaluate different doses of methylene blue on the viability of primary cultured keratinocytes from patients with large burn. They will be included 10 patients with major burn patients and 10 healthy without burning. (AU)